Heart failure & cardiomyopathies

Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk

JACC Heart FailPublished Secondary analysis of the STRONG-HF randomised trial

An erratum to this article was published (JACC Heart Fail, Oct 2026 ↗)

Primary result · All-cause death or HF readmission by MAGGIC risk scoreResult — go to the resultHazard ratio 0.66 95% CI 0.50–0.86

Authors' conclusion

HIC led to better use of GDMT and lower HF-related morbidity and mortality compared with UC, regardless of the underlying HF risk profile.

Study context

Population
Patients with acute heart failure (HF), stratified by MAGGIC HF risk score1,062 with MAGGIC score
Participants
1,078 patients
Comparison
High-intensity care vs usual care
Primary endpoint
All-cause death or first HF rehospitalization
Follow-up
Day 180
Methodological detailssubgroup analysis by MAGGIC risk score
  • Subgroup analysis by MAGGIC risk score

Primary result

As reported in the abstract

All-cause death or HF readmission by MAGGIC risk score

Hazard ratio

0.66

95% CI 0.50–0.86

HICvs UC
HR 0.66 (95% CI 0.50–0.86)
Incidence in MAGGIC tertiles 1, 2 and 3
16.3%, 18.9%, and 23.2%
High-intensity care (HIC) vs usual care (UC) across MAGGIC tertiles 1, 2 and 3 (categorical), as printed
HR: 0.51; 95% CI: 0.62-0.68
Effect consistent across MAGGIC tertiles and continuous MAGGIC score
interaction nonsignificant

Further findings

Guideline-directed medical therapy (GDMT) prescriptions achieved by medication class

Higher with HIC vs UC, no difference by MAGGIC tertile
interaction nonsignificant

Safety

Adverse events

Higher rate with HIC, not differing by MAGGIC tertile
interaction nonsignificant

Original publication

Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk. JACC Heart Fail. Published 12 May 2024. doi:10.1016/j.jchf.2024.04.017

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.